The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Psychotic Disorders

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Psychotic Disorders


Psychiatry related information on Psychotic Disorders


High impact information on Psychotic Disorders


Chemical compound and disease context of Psychotic Disorders


Biological context of Psychotic Disorders


Anatomical context of Psychotic Disorders


Gene context of Psychotic Disorders

  • Based on the genetic and functional evidence that DISC1 may be associated with schizophrenia, we sequenced portions of DISC1 in 28 unrelated probands with schizophrenia and six unrelated probands with schizoaffective disorder, ascertained as part of a large sibpair study [29].
  • The mutation was identified in three siblings with PEO, one of them additionally suffered from schizoaffective disorder [30].
  • Our findings suggest that the expression of DRD3 mRNA is reduced in schizophrenia and bipolar disorder, supporting the hypothesis of distorted homeostasis of dopamine receptor subtypes in psychotic disorder [31].
  • Analysis of diagnostic subgroups within the "all affecteds group" showed an association of COMT in patients with psychotic disorders as well as in cases with affective illness although the associated variants differed [32].
  • These results suggest a specific link between reelin-related neuronal pathology and dopamine involvement in the pathophysiology of psychotic disorders [33].

Analytical, diagnostic and therapeutic context of Psychotic Disorders


  1. Abnormal rapid eye movement latencies in schizophrenia. Zarcone, V.P., Benson, K.L., Berger, P.A. Arch. Gen. Psychiatry (1987) [Pubmed]
  2. Hyperprolinemia is a risk factor for schizoaffective disorder. Jacquet, H., Demily, C., Houy, E., Hecketsweiler, B., Bou, J., Raux, G., Lerond, J., Allio, G., Haouzir, S., Tillaux, A., Bellegou, C., Fouldrin, G., Delamillieure, P., Ménard, J.F., Dollfus, S., D'Amato, T., Petit, M., Thibaut, F., Frébourg, T., Campion, D. Mol. Psychiatry (2005) [Pubmed]
  3. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Henderson, D.C., Copeland, P.M., Daley, T.B., Borba, C.P., Cather, C., Nguyen, D.D., Louie, P.M., Evins, A.E., Freudenreich, O., Hayden, D., Goff, D.C. The American journal of psychiatry. (2005) [Pubmed]
  4. Antipsychotic-induced weight gain and therapeutic response: a differential association. Czobor, P., Volavka, J., Sheitman, B., Lindenmayer, J.P., Citrome, L., McEvoy, J., Cooper, T.B., Chakos, M., Lieberman, J.A. Journal of clinical psychopharmacology. (2002) [Pubmed]
  5. Familial association of albinism and schizophrenia. Clarke, D.J., Buckley, M.E. The British journal of psychiatry : the journal of mental science. (1989) [Pubmed]
  6. Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Hamshere, M.L., Bennett, P., Williams, N., Segurado, R., Cardno, A., Norton, N., Lambert, D., Williams, H., Kirov, G., Corvin, A., Holmans, P., Jones, L., Jones, I., Gill, M., O'Donovan, M.C., Owen, M.J., Craddock, N. Arch. Gen. Psychiatry (2005) [Pubmed]
  7. 'Schizoaffective disorder': dead or alive? Tsuang, M.T. Arch. Gen. Psychiatry (1979) [Pubmed]
  8. Mental disorder in elderly suicides: a case-control study. Waern, M., Runeson, B.S., Allebeck, P., Beskow, J., Rubenowitz, E., Skoog, I., Wilhelmsson, K. The American journal of psychiatry. (2002) [Pubmed]
  9. Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Bertolino, A., Sciota, D., Brudaglio, F., Altamura, M., Blasi, G., Bellomo, A., Antonucci, N., Callicott, J.H., Goldberg, T.E., Scarabino, T., Weinberger, D.R., Nardini, M. The American journal of psychiatry. (2003) [Pubmed]
  10. Characteristics of patients with the highest plasma catecholamine metabolite levels. Bowers, M.B., Swigar, M.E., Hoffman, F.J., Goicoechea, N. The American journal of psychiatry. (1988) [Pubmed]
  11. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. Csernansky, J.G., Mahmoud, R., Brenner, R. N. Engl. J. Med. (2002) [Pubmed]
  12. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Potkin, S.G., Saha, A.R., Kujawa, M.J., Carson, W.H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., Marder, S.R. Arch. Gen. Psychiatry (2003) [Pubmed]
  13. Dopamine antagonists and the development of breast cancer. Wang, P.S., Walker, A.M., Tsuang, M.T., Orav, E.J., Glynn, R.J., Levin, R., Avorn, J. Arch. Gen. Psychiatry (2002) [Pubmed]
  14. Lithium in the treatment of schizophrenia and schizoaffective disorders. Prien, R.J. Arch. Gen. Psychiatry (1979) [Pubmed]
  15. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Laruelle, M., Abi-Dargham, A., Casanova, M.F., Toti, R., Weinberger, D.R., Kleinman, J.E. Arch. Gen. Psychiatry (1993) [Pubmed]
  16. Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial. Siris, S.G., Morgan, V., Fagerstrom, R., Rifkin, A., Cooper, T.B. Arch. Gen. Psychiatry (1987) [Pubmed]
  17. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Rao, P.A., Pickar, D., Gejman, P.V., Ram, A., Gershon, E.S., Gelernter, J. Arch. Gen. Psychiatry (1994) [Pubmed]
  18. Methylation hypothesis. Baldessarini, R.J., Stramentinoli, G., Lipinski, J.F. Arch. Gen. Psychiatry (1979) [Pubmed]
  19. Association between catechol O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorder. Lachman, H.M., Nolan, K.A., Mohr, P., Saito, T., Volavka, J. The American journal of psychiatry. (1998) [Pubmed]
  20. A study of chromosome 4p markers and dopamine D5 receptor gene in schizophrenia and bipolar disorder. Asherson, P., Mant, R., Williams, N., Cardno, A., Jones, L., Murphy, K., Collier, D.A., Nanko, S., Craddock, N., Morris, S., Muir, W., Blackwood, B., McGuffin, P., Owen, M.J. Mol. Psychiatry (1998) [Pubmed]
  21. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Kroeze, W.K., Roth, B.L. Biol. Psychiatry (1998) [Pubmed]
  22. The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders. Strakowski, S.M., Keck, P.E., Wong, Y.W., Thyrum, P.T., Yeh, C. Journal of clinical psychopharmacology. (2002) [Pubmed]
  23. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Williams, J.M., Ziedonis, D.M., Abanyie, F., Steinberg, M.L., Foulds, J., Benowitz, N.L. Schizophr. Res. (2005) [Pubmed]
  24. Middle ear muscle activity during REM sleep in schizophrenic, schizoaffective and depressed patients. Benson, K.L., Zarcone, V.P. The American journal of psychiatry. (1982) [Pubmed]
  25. Postictal and chronic psychoses in patients with temporal lobe epilepsy. Umbricht, D., Degreef, G., Barr, W.B., Lieberman, J.A., Pollack, S., Schaul, N. The American journal of psychiatry. (1995) [Pubmed]
  26. Impaired antioxidant defense at the onset of psychosis. Mukerjee, S., Mahadik, S.P., Scheffer, R., Correnti, E.E., Kelkar, H. Schizophr. Res. (1996) [Pubmed]
  27. Cerebrospinal fluid levels of phenylacetic acid in mental illness: behavioral associations and response to neuroleptic treatment. Sharma, R.P., Faull, K., Javaid, J.I., Davis, J.M. Acta psychiatrica Scandinavica. (1995) [Pubmed]
  28. Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder. O'Donnell, M.C., Catts, S.V., Ward, P.B., Liebert, B., Lloyd, A., Wakefield, D., McConaghy, N. Psychiatry research. (1996) [Pubmed]
  29. A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder. Sachs, N.A., Sawa, A., Holmes, S.E., Ross, C.A., DeLisi, L.E., Margolis, R.L. Mol. Psychiatry (2005) [Pubmed]
  30. A novel ANT1 gene mutation with probable germline mosaicism in autosomal dominant progressive external ophthalmoplegia. Deschauer, M., Hudson, G., Müller, T., Taylor, R.W., Chinnery, P.F., Zierz, S. Neuromuscul. Disord. (2005) [Pubmed]
  31. Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Vogel, M., Pfeifer, S., Schaub, R.T., Grabe, H.J., Barnow, S., Freyberger, H.J., Cascorbi, I. Neuropsychobiology (2004) [Pubmed]
  32. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Funke, B., Malhotra, A.K., Finn, C.T., Plocik, A.M., Lake, S.L., Lencz, T., DeRosse, P., Kane, J.M., Kucherlapati, R. Behavioral and brain functions [electronic resource] : BBF. (2005) [Pubmed]
  33. Preferential alterations in the mesolimbic dopamine pathway of heterozygous reeler mice: an emerging animal-based model of schizophrenia. Ballmaier, M., Zoli, M., Leo, G., Agnati, L.F., Spano, P. Eur. J. Neurosci. (2002) [Pubmed]
  34. Psychiatric problems in homeless men. Lifetime psychosis, substance use, and current distress in new arrivals at New York City shelters. Susser, E., Struening, E.L., Conover, S. Arch. Gen. Psychiatry (1989) [Pubmed]
  35. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Henderson, D.C., Cagliero, E., Copeland, P.M., Borba, C.P., Evins, E., Hayden, D., Weber, M.T., Anderson, E.J., Allison, D.B., Daley, T.B., Schoenfeld, D., Goff, D.C. Arch. Gen. Psychiatry (2005) [Pubmed]
  36. Mutation screening of the Wolfram syndrome gene in psychiatric patients. Torres, R., Leroy, E., Hu, X., Katrivanou, A., Gourzis, P., Papachatzopoulou, A., Athanassiadou, A., Beratis, S., Collier, D., Polymeropoulos, M.H. Mol. Psychiatry (2001) [Pubmed]
  37. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. Volavka, J., Czobor, P., Citrome, L., McQuade, R.D., Carson, W.H., Kostic, D., Hardy, S., Marcus, R. The Journal of clinical psychiatry. (2005) [Pubmed]
  38. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies. Keck, P.E., Reeves, K.R., Harrigan, E.P. Journal of clinical psychopharmacology. (2001) [Pubmed]
WikiGenes - Universities